Century Therapeutics (IPSC) Projected to Announce Quarterly Earnings on Thursday

Century Therapeutics (NASDAQ:IPSC) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Century Therapeutics to post earnings of ($0.11) per share and revenue of $2.1670 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. On average, analysts expect Century Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Century Therapeutics Trading Down 1.0%

IPSC opened at $1.98 on Tuesday. Century Therapeutics has a 1-year low of $0.44 and a 1-year high of $3.04. The stock’s fifty day simple moving average is $2.21 and its 200 day simple moving average is $2.23. The stock has a market cap of $357.09 million, a PE ratio of -1.74 and a beta of 1.57.

Analysts Set New Price Targets

IPSC has been the topic of several research reports. Mizuho started coverage on shares of Century Therapeutics in a report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price objective on the stock. Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright raised their target price on shares of Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.75.

Institutional Investors Weigh In On Century Therapeutics

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Century Therapeutics by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock worth $454,000 after purchasing an additional 10,806 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Century Therapeutics by 64.1% during the third quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock worth $180,000 after purchasing an additional 140,891 shares during the period. Two Sigma Investments LP raised its position in shares of Century Therapeutics by 59.2% in the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after buying an additional 338,902 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Century Therapeutics by 483.1% in the third quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after buying an additional 195,573 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Century Therapeutics in the second quarter valued at approximately $248,000. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.